Ethosuximide
Ethosuximide, Zarontin (ethosuximide) is a small molecule pharmaceutical. Ethosuximide was first approved as Zarontin on 1982-01-01. It is used to treat absence epilepsy and epilepsy in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| nervous system diseases | D009422 |
Trade Name
FDA
EMA
Ethosuximide, Zarontin (discontinued: Ethosuximide)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| ethosuximide | ANDA | 2024-10-09 |
| zarontin | New Drug Application | 2024-07-15 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| epilepsy | EFO_0000474 | D004827 | G40.9 |
| absence epilepsy | HP_0011147 | D004832 | G40.A |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
14 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Epilepsy | D004827 | EFO_0000474 | G40.9 | — | — | 2 | 2 | 2 | 6 |
| Intellectual disability | D008607 | EFO_0003847 | F73 | — | — | — | 1 | — | 1 |
| Drug resistant epilepsy | D000069279 | — | — | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Syndrome | D013577 | — | — | — | 2 | 1 | — | — | 3 |
| Irritable bowel syndrome | D043183 | EFO_0000555 | K58 | — | 1 | 1 | — | — | 2 |
| Absence epilepsy | D004832 | HP_0011147 | G40.A | — | — | 2 | — | — | 2 |
| Ketogenic diet | D055423 | — | — | — | — | 1 | — | — | 1 |
| Seizures | D012640 | HP_0002069 | G40.4 | — | — | 1 | — | — | 1 |
| Abdominal pain | D015746 | HP_0002027 | R10.9 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neuralgia | D009437 | EFO_0009430 | — | — | 2 | — | — | — | 2 |
| Complex regional pain syndromes | D020918 | EFO_1001998 | — | — | 1 | — | — | — | 1 |
| Reflex sympathetic dystrophy | D012019 | EFO_1001147 | G90.5 | — | 1 | — | — | — | 1 |
| Somatoform disorders | D013001 | — | F45 | — | 1 | — | — | — | 1 |
| Pain | D010146 | EFO_0003843 | R52 | — | 1 | — | — | — | 1 |
| Neoplasms | D009369 | — | C80 | — | 1 | — | — | — | 1 |
| Peripheral nervous system diseases | D010523 | HP_0009830 | G64 | — | 1 | — | — | — | 1 |
| Migraine disorders | D008881 | EFO_0003821 | G43 | 1 | 1 | — | — | — | 1 |
| Headache | D006261 | HP_0002315 | R51 | 1 | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Depression | D003863 | — | F33.9 | 1 | — | — | — | — | 1 |
| Treatment-resistant depressive disorder | D061218 | — | — | 1 | — | — | — | — | 1 |
| Depressive disorder | D003866 | EFO_1002014 | F32.A | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Financial stress | D000086522 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Ethosuximide |
| INN | ethosuximide |
| Description | Ethosuximide is a dicarboximide that is pyrrolidine-2,5-dione in which the hydrogens at position 3 are substituted by one methyl and one ethyl group. An antiepileptic, it is used in the treatment of absence seizures and may be used for myoclonic seizures, but is ineffective against tonic-clonic seizures. It has a role as an anticonvulsant, a geroprotector and a T-type calcium channel blocker. It is a pyrrolidinone and a dicarboximide. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCC1(C)CC(=O)NC1=O |
Identifiers
| PDB | — |
| CAS-ID | 77-67-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL696 |
| ChEBI ID | 4887 |
| PubChem CID | 3291 |
| DrugBank | DB00593 |
| UNII ID | 5SEH9X1D1D (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Ethosuximide
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 3,123 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,406 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use